Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | CFTR | P13569 | 3/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 6/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.33 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.33 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26405293 | 0.84 | CYP17A1 (0.41) | LMNAPOLBRXFP1AAK1MAP4K4 | |
| SCHEMBL5558080 | 0.81 | LMNA (0.41) | LMNAPOLBRXFP1CFTRAAK1 | |
| SCHEMBL26129255 | 0.81 | CFTR (0.35) | CFTRAR | |
| SCHEMBL30538182 | 0.81 | LMNA (0.44) | LMNAPOLBRXFP1AR | |
| SCHEMBL29174185 | 0.81 | LMNA (0.44) | LMNAPOLBRXFP1AR | |
| SCHEMBL26405735 | 0.81 | AAK1 (0.41) | AAK1MAP4K4 | |
| SCHEMBL5563358 | 0.77 | LMNA (0.44) | LMNAPOLBRXFP1CFTRAAK1 | |
| SCHEMBL2316853 | 0.77 | LMNA (0.44) | LMNAPOLBRXFP1CFTRAAK1 | |
| SCHEMBL29446519 | 0.77 | LMNA (0.44) | LMNAPOLBRXFP1CFTRAAK1 | |
| SCHEMBL29430784 | 0.77 | LMNA (0.44) | LMNAPOLBRXFP1CFTRAAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250339552-A1 | ANTIBODY-DRUG CONJUGATES TARGETING FOLATE RECEPTOR ALPHA AND METHODS OF USE | ZYMEWORKS BC INC (CA) | 2025-11-06 | — | — | US | disclosed |
| US-12433952-B2 | Antibody-drug conjugates targeting folate receptor alpha and methods of use | ZYMEWORKS BC INC. (CA) | 2025-10-07 | — | — | US | disclosed |
| US-20250295799-A1 | ANTIBODY-DRUG CONJUGATES TARGETING GLYPICAN-3 AND METHODS OF USE | ZYMEWORKS BC INC. (CA) | 2025-09-25 | — | — | US | disclosed |
| EP-4605426-A1 | ANTIBODY-DRUG CONJUGATES TARGETING NAPI2B AND METHODS OF USE | Zymeworks BC Inc. (CA) | 2025-08-27 | — | — | EP | disclosed |
| US-20250235548-A1 | ANTIBODY-DRUG CONJUGATES TARGETING NAPI2B AND METHODS OF USE | ZYMEWORKS BC INC. (CA) | 2025-07-24 | — | — | US | disclosed |
| CN-119948062-A | NAPI 2B-targeted antibody-drug conjugates and methods of use thereof | 酵活英属哥伦比亚有限公司 | 2025-05-06 | — | — | CN | disclosed |
| WO-2025081282-A1 | ANTI-NAPI2B ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | ZYMEWORKS BC INC. (CA) | 2025-04-24 | — | — | WO | disclosed |
| EP-4499698-A1 | ANTIBODY-DRUG CONJUGATES TARGETING FOLATE RECEPTOR ALPHA AND METHODS OF USE | Zymeworks BC Inc. (CA) | 2025-02-05 | — | — | EP | disclosed |
| US-20240424125-A1 | ANTIBODY-DRUG CONJUGATES TARGETING FOLATE RECEPTOR ALPHA AND METHODS OF USE | ZYMEWORKS BC INC. (CA) | 2024-12-26 | — | — | US | disclosed |
| CN-118922447-A | Folate receptor alpha-targeting antibody-drug conjugates and methods of use | 酵活英属哥伦比亚有限公司 | 2024-11-08 | — | — | CN | disclosed |
| US-20240269309-A1 | CAMPTOTHECIN ANALOGUES, CONJUGATES AND METHODS OF USE | ZYMEWORKS INC. (CA) | 2024-08-15 | — | — | US | disclosed |
| WO-2024082055-A1 | ANTIBODY-DRUG CONJUGATES TARGETING NAPI2B AND METHODS OF USE | ZYMEWORKS BC INC. (CA) | 2024-04-25 | — | — | WO | disclosed |
| CN-117715914-A | Camptothecin analogs, conjugates, and methods of use | 酵活英属哥伦比亚有限公司 | 2024-03-15 | — | — | CN | disclosed |
| WO-2023178452-A1 | ANTIBODY-DRUG CONJUGATES TARGETING FOLATE RECEPTOR ALPHA AND METHODS OF USE | ZYMEWORKS BC INC. (CA) | 2023-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240269309-A1 | CAMPTOTHECIN ANALOGUES, CONJUGATES AND METHODS OF USE | TOP2A, TOP1, TOP2B | LMNA 1892/4885POLB 348/4885RXFP1 4390/4885 |
| US-20250339552-A1 | ANTIBODY-DRUG CONJUGATES TARGETING FOLATE RECEPTOR ALPHA AND METHODS OF USE | FOLR1, FOLR2, DHFR | LMNA 3852/4885POLB 1958/4885RXFP1 281/4885 |
| US-12433952-B2 | Antibody-drug conjugates targeting folate receptor alpha and methods of use | FOLR1, FOLR2, DHFR | LMNA 3852/4885POLB 1958/4885RXFP1 281/4885 |
| US-20250235548-A1 | ANTIBODY-DRUG CONJUGATES TARGETING NAPI2B AND METHODS OF USE | SLC34A2, SLC20A2, SLC34A1 | LMNA 4291/4885POLB 885/4885RXFP1 4713/4885 |
| US-20250295799-A1 | ANTIBODY-DRUG CONJUGATES TARGETING GLYPICAN-3 AND METHODS OF USE | B3GAT3, GALNT3, GOLGA3 | LMNA 2609/4885POLB 4566/4885RXFP1 2761/4885 |
| US-20240424125-A1 | ANTIBODY-DRUG CONJUGATES TARGETING FOLATE RECEPTOR ALPHA AND METHODS OF USE | FOLR1, FOLR2, DHFR | LMNA 3852/4885POLB 1958/4885RXFP1 281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.